arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Denali Therapeutics Inc.

DNLI
$19.72 ▼ -1.22 (-5.83%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
41 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Denali Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.7B
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -10.8% ↗
FCF / Share $-0.63 ↘
Trailing P/E 53.3x
Price / Book 3.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

41-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$17.78M
↑ +393.3% —
Net Income Profit after all expenses
$70.13M
↑ +155.0% —
Operating Margin Operating profit as % of sales
58.0%
↑ +116.9% —
FCF / Share Free cash flow per share
$-0.63
↓ -20.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
17
Cash Quality ↑
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 11 years · 41 quarters